EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies

Piotr Rutkowski, Dariusz M Kowalski, Victor Moreno, Aitana Calvo, Fiona Thistlethwaite, Ruth Plummer, Douglas Steinbach, John Loffredo, Sydney Akapeme, Daniel Jonathan, Vinod Philip, Angela Girvin und 3 weitere

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04457-1 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Piotr Rutkowski und 14 weiteren Autor:innen. Beteiligte Einrichtung: Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. rutkowskip@coi.waw.pl. Hauptthemen laut MEDLINE: Neoplasms, Antibodies, Monoclonal, Humanized, Programmed Cell Death 1 Receptor, Antineoplastic Agents, Immunological. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Pharmacokinetics, pharmacodynamics, safety, and efficacy of subcutaneous cetrelimab were assessed in Parts (P)3 and 4 of the phase I LUC1001 study in patients with advanced/refractory solid tumors who progressed on or wereineligible for standard treatment and had no prior PD-1/PD-L1/PD-L2 treatment. METHODS: In P3, low-concentration cetrelimab (30 mg/mL) was administered subcutaneously at 600 mg with a 6-week interval between doses 1 and 2, then every 3 weeks (Q3W). Based on P3 pharmacokinetic and safety findings, high-concentration cetrelimab (150 mg/mL) was administered subcutaneously at a 900 mg loading dose followed by 600 mg Q3W in P4. RESULTS: Among 30 enrolled patients (P3, n = 11; P4, n = 19), median age was 54.5y; 76.7% received ≥ 3 prior lines of therapy. Median duration of treatment was 2.1mo. Treatment-related adverse events (AEs) occurred in 70% of patients, including 23.3% with grade ≥ 3 treatment-related AEs and 30.0% immune-related AEs; no treatment-related serious AEs or systemic infusion-related reactions occurred. After 3.7mo median follow-up, 2 patients (6.7%) achieved durable responses and 4 patients (13.3%) had stable disease for ≥ 24 weeks. Pharmacokinetic data showed that adding a 900 mg loading dose to the 600 mg Q3W subcutaneous regimen shortened the time to reach target recommended phase 2 dose (RP2D) exposures, making it a suitable intravenous alternative. Maximum PD-1 receptor occupancy was achieved with both formulations. Anti-cetrelimab antibodies were detected in 4 patients (13.3%); none were neutralizing. CONCLUSIONS: RP2D of subcutaneous cetrelimab was established as a loading dose of 900 mg followed by 600 mg Q3W. Subcutaneous cetrelimab demonstrated characteristics consistent with prior characterization of intravenous cetrelimab. Trial registration NCT02908906 at ClinicalTrials.gov, September 21, 2016; EudraCT 2016-002,017-22 at clinicaltrialsregister.eu, Jan 11, 2017.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntibodies, Monoclonal, HumanizedProgrammed Cell Death 1 ReceptorAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsHumansFemaleMaleMiddle AgedAdultAgedInjections, Subcutaneous

Stichwörter der Autor:innen

CetrelimabPD-1 inhibitorPharmacokineticsPhase 1SafetySubcutaneous

Substanzen

Antibodies, Monoclonal, HumanizedProgrammed Cell Death 1 ReceptorAntineoplastic Agents, ImmunologicalPDCD1 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. rutkowskip@coi.waw.pl.
  • Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Medical Oncology, START Madrid-FJD, University Hospital Fundación Jiménez Diaz, Madrid, Spain.
  • Gregorio Marañon University General Hospital, Madrid, Spain.
  • The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom.
  • Newcastle University, Newcastle Upon Tyne, United Kingdom.

Förderung

  • Johnson and Johnson

Zitieren

APA

Rutkowski, P., Kowalski, D. M., Moreno, V., Calvo, A., Thistlethwaite, F., Plummer, R., Steinbach, D., Loffredo, J., Akapeme, S., Jonathan, D., Philip, V., Girvin, A., Hampras, S., Hellemans, P., & Bulat, I. (2026). A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04457-1

Vancouver

Rutkowski P, Kowalski DM, Moreno V, Calvo A, Thistlethwaite F, Plummer R, et al. A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04457-1

BibTeX
@article{Rutkowski2026,
  author = {Rutkowski, Piotr and Kowalski, Dariusz M and Moreno, Victor and Calvo, Aitana and Thistlethwaite, Fiona and Plummer, Ruth and Steinbach, Douglas and Loffredo, John and Akapeme, Sydney and Jonathan, Daniel and Philip, Vinod and Girvin, Angela and Hampras, Shalaka and Hellemans, Peter and Bulat, Iurie},
  title = {A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04457-1}
}
Kostenlos starten →